Denis Arikci
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Denis Arikci has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Friederike Holze
Clinical Pharmacology and Toxicology, Department of Biomedicine and Department of Clinical Research, University Hospital Basel, Basel, Switzerland
2 shared publications - Matthias E. Liechti
Clinical Pharmacology and Toxicology, Department of Biomedicine and Department of Clinical Research, University Hospital Basel and University of Basel, Switzerland
2 shared publications - Aaron Klaiber
Division of Clinical Pharmacology and Toxicology, Department of Biomedicine and Department of Clinical Research, University Hospital Basel and University of Basel, Basel, Switzerland
1 shared publication - Anna M. Becker
Division of Clinical Pharmacology and Toxicology, Department of Biomedicine and Department of Clinical Research, University Hospital Basel, Basel, Switzerland
1 shared publication - Deborah Rudin
Division of Clinical Pharmacology and Toxicology, Department of Biomedicine, University Hospital Basel, Basel, Switzerland; Division of Clinical Pharmacology and Toxicology, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland
1 shared publication - Dino Luethi
Division of Clinical Pharmacology and Toxicology, Department of Biomedicine and Department of Clinical Research, University Hospital Basel and University of Basel, Basel, Switzerland
1 shared publication
Latest Publications
- Open Access
- 26 December 2025
- Published by SAGE Publications in Journal of Psychopharmacology
- Vol. 40 (5) , 850-862
The 3D-ASCr scale: A revalidation of the core dimensions of the Altered States of Consciousness Rating Scale 5D(11)-ASC for psychedelic research
Background: The Altered States of Consciousness Scale (3/5D-ASC or 11-ASC) is widely used to assess non-ordinary states of consciousness, particularly for psychedelic research. However, its original dimensional model (3D-ASC within 5D-ASC) and later 11-subscale structure (11-ASC) have a hierarchically incompatible higher/lower-order structure. Although the 11-ASC offers superior model fit, the 3D-ASC remains widely used for summarizing broader experiential domains. Aims: We wanted to provide an updated, psychometrically revalidated version of the ASC. We tested whether the 42-item 11-ASC could be integrated into a coherent three-dimensional framework. We further hypothesized that this revised model would outperform the original 66-item 3D-ASC while preserving its conceptual clarity. Methods: Data from 901 5D-ASC questionnaires from 398 healthy participants across 16 randomized, mostly placebo-controlled psychedelic (lysergic acid diethylamide, psilocybin, mescaline, and N , N -dimethyltryptamine) studies were split for exploratory and confirmatory factor analysis. We compared the 3D-ASC and 11-ASC in terms of reliability and model fit, and tested whether the 11-ASC could be summarized within a three-dimensional model. Results: Ten of the 11 subscales formed three higher-order dimensions—Positive (PosE), Distressing (DisE), and Perceptual (PerE) effects—mirroring the 3D-ASC but with improved fit. We propose this as the 3D-ASCr scale. The Anxiety subscale could not be integrated due to consistent floor effects (low anxiety in the sample), but given its clinical relevance, it is retained within 3D-ASCr (as part of DisE or a standalone subscale). Conclusion: The 3D-ASCr is an updated version of the ASC and is recommended for use with classic serotonergic psychedelics in both clinical practice and research.
- 26 December 2025
- Published by SAGE Publications in Journal of Psychopharmacology
- Vol. 40 (5) , 850-862
Open AccessThe 3D-ASCr scale: A revalidation of the core dimensions of the Altered States of Consciousness Rating Scale 5D(11)-ASC for psychedelic research
Background: The Altered States of Consciousness Scale (3/5D-ASC or 11-ASC) is widely used to assess non-ordinary states of consciousness, particularly for psychedelic research. However, its original dimensional model (3D-ASC within 5D-ASC) and later 11-subscale structure (11-ASC) have a hierarchically incompatible higher/lower-order structure. Although the 11-ASC offers superior model fit, the 3D-ASC remains widely used for summarizing broader experiential domains. Aims: We wanted to provide an updated, psychometrically revalidated version of the ASC. We tested whether the 42-item 11-ASC could be integrated into a coherent three-dimensional framework. We further hypothesized that this revised model would outperform the original 66-item 3D-ASC while preserving its conceptual clarity. Methods: Data from 901 5D-ASC questionnaires from 398 healthy participants across 16 randomized, mostly placebo-controlled psychedelic (lysergic acid diethylamide, psilocybin, mescaline, and N , N -dimethyltryptamine) studies were split for exploratory and confirmatory factor analysis. We compared the 3D-ASC and 11-ASC in terms of reliability and model fit, and tested whether the 11-ASC could be summarized within a three-dimensional model. Results: Ten of the 11 subscales formed three higher-order dimensions—Positive (PosE), Distressing (DisE), and Perceptual (PerE) effects—mirroring the 3D-ASC but with improved fit. We propose this as the 3D-ASCr scale. The Anxiety subscale could not be integrated due to consistent floor effects (low anxiety in the sample), but given its clinical relevance, it is retained within 3D-ASCr (as part of DisE or a standalone subscale). Conclusion: The 3D-ASCr is an updated version of the ASC and is recommended for use with classic serotonergic psychedelics in both clinical practice and research.
- Open Access
- 28 April 2025
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 53 (6) , 100086
Liquid chromatography–tandem mass spectrometry–based pharmacokinetic and metabolic analysis of 4-bromo-2,5-dimethoxyphenethylamine and its metabolites in human plasma
- 28 April 2025
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 53 (6) , 100086
Open AccessLiquid chromatography–tandem mass spectrometry–based pharmacokinetic and metabolic analysis of 4-bromo-2,5-dimethoxyphenethylamine and its metabolites in human plasma